A
Alin Gherasim
Researcher at Carlos III Health Institute
Publications - 44
Citations - 1105
Alin Gherasim is an academic researcher from Carlos III Health Institute. The author has contributed to research in topics: Influenza vaccine & Medicine. The author has an hindex of 15, co-authored 30 publications receiving 842 citations.
Papers
More filters
2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1) pdm09 and B among elderly people in Europe: results from the I-MOVE plus project
Marc Rondy,Amparo Larrauri,Itziar Casado,V. Alfonsi,Daniela Pitigoi,Odile Launay,R. K. Syrjanen,Giedre Gefenaite,Ausenda Machado,Vesna Višekruna Vučina,Judith Krisztina Horváth,Iwona Paradowska-Stankiewicz,Sierk D Marbus,Alin Gherasim,Jorge Díaz-González,Caterina Rizzo,Alina Elena Ivanciuc,F. Galtier,Niina Ikonen,Aukse Mickiene,Verónica Gómez,S. Kurecic Filipovic,Annamária Ferenczi,M. R. Korcinska,R. van Gageldonk-Lafeber,Marta Valenciano +25 more
Journal ArticleDOI
I-MOVE multicentre case–control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
Esther Kissling,Baltazar Nunes,Chris Robertson,Chris Robertson,Marta Valenciano,Annicka Reuss,Amparo Larrauri,Jean Cohen,Beatrix Oroszi,Caterina Rizzo,Ausenda Machado,Daniela Pitigoi,Lisa Domegan,Iwona Paradowska-Stankiewicz,Udo Buchholz,Alin Gherasim,Isabelle Daviaud,Judit Krisztina Horváth,Antonino Bella,Emilia Lupulescu,Joan O Donnell,Monika Roberta Korczyńska,Alain Moren +22 more
TL;DR: To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed, combined I-MOVE data from 2010/11 to 2014/15 is studied.
Journal ArticleDOI
Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies
Marc Rondy,Esther Kissling,Hanne-Dorthe Emborg,Alin Gherasim,Richard Pebody,Ramona Trebbien,Francisco Pozo,Amparo Larrauri,Jim McMenamin,Marta Valenciano,I-Move +10 more
TL;DR: Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, and 55 to 68% against influenza A(H1N1)pdm09.
Journal ArticleDOI
Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15.
Marta Valenciano,Esther Kissling,Annicka Reuss,Caterina Rizzo,Alin Gherasim,Judit Krisztina Horváth,Lisa Domegan,Daniela Pitigoi,Ausenda Machado,Iwona Paradowska-Stankiewicz,Antonino Bella,Amparo Larrauri,Annamária Ferenczi,Joan O´Donell,Mihaela Lazar,Pedro Pechirra,Monika Roberta Korczyńska,Francisco Pozo,Alain Moren,I-Move multicentre case-control team +19 more
TL;DR: A multicentre case-control study in eight European countries to measure 2014/15 influenza vaccine effectiveness (VE) against medically-attended influenza-like illness (ILI) laboratory-confirmed as influenza found the low VE against A(H3N2) is consistent with the reported mismatch between circulating and vaccine strains.
Journal ArticleDOI
Epidemiological changes in leishmaniasis in Spain according to hospitalization-based records, 1997-2011: raising awareness towards leishmaniasis in non-HIV patients.
Zaida Herrador,Alin Gherasim,B. Carolina Jimenez,Maria del sol Granados,Juan Victor San Martin,Pilar Aparicio +5 more
TL;DR: A significant increase of hospitalization in the absence of HIV co-infection is suggested, with a predomination of VL, and clinicians in Spain should be aware of leishmaniasis not only in the HIV population but also in non HIV patients, especially for those having immunosuppression as an associate condition.